GlassScriptPhysician profile
Paul D Brydon
NPI 1912208836
$2,204.20
in general payments reported to CMS, 2019-2025
25 companies · $391 in 2025
The $391 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $982 · 2020: $53.63 · 2021: $21.35 · 2022: $61.69 · 2023: $394 · 2024: $300 · 2025: $391.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,086.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,085.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $287.45 | 2019-2025 | Mounjaro, Jardiance |
| Glaxosmithkline, LLC. | $253.56 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Exact Sciences Corporation | $213.64 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $196.67 | 2019-2025 | Gardasil 9, Capvaxive, Vaxelis |
| Abbvie INC. | $177.80 | 2019-2025 | Ubrelvy |
| Novo Nordisk INC | $153.15 | 2019-2025 | Ozempic, Rybelsus |
| Abbott Laboratories | $126.90 | 2019-2025 | Freestyle Libre 3 |
| Pfizer INC. | $110.67 | 2019-2025 | |
| Dynavax Technologies Corporation | $94.42 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $78.39 | 2023-2025 | Airsupra, Farxiga |
| Janssen Pharmaceuticals, INC | $67.37 | 2019 | |
| Shire North American Group INC | $64.62 | 2019 | |
| Valeritas, INC. | $59.11 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.91 | 2019-2024 | Jardiance |
| Astellas Pharma US INC | $46.09 | 2019-2024 | Veozah |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $41.72 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $32.34 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $31.62 | 2019-2022 | |
| Amarin Pharma, INC. | $29.43 | 2019-2020 | |
| Antares Pharma, INC. | $18.50 | 2019 | |
| Sanofi-Aventis U.S. LLC | $16.79 | 2019 | |
| Amgen INC. | $16.10 | 2025 | Evenity, Prolia |
| Idorsia Pharmaceuticals US INC | $15.55 | 2023 | Quviviq |
| Phathom Pharmaceuticals, INC. | $13.34 | 2025 | Voquezna |
| Therapeuticsmd, INC. | $11.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Brydon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.